

# J1306

## Permanent J-code now available for LEQVIO<sup>®</sup> Effective July 1, 2022 for all sites of care

For patients who received LEQVIO on or after July 1, 2022, you must use permanent J-code J1306. The permanent J-code enables providers and office staff to code with specificity, for claims processing purposes, after LEQVIO is given to a patient.<sup>1,2</sup>

<b>J-code description<sup>1</sup></b>	<b>J1306: Injection, inclisiran, 1 mg</b>
<b>Package strength<sup>3</sup></b>	<b>284 mg/1.5 mL single-dose prefilled syringe</b>
<b>Billing units</b>	<b>284</b>
<b>NDC number<sup>3</sup></b>	<b>10-digit: 0078-1000-60</b> <b>11-digit: 00078-1000-60</b>

**The permanent J-code replaces the miscellaneous J-code J3490 and C-code C9399 if LEQVIO is administered on or after July 1, 2022.**

The information herein is provided for educational purposes only. Novartis cannot guarantee insurance coverage or reimbursement. Coverage and reimbursement may vary significantly by payer, plan, patient, and setting of care. It is the sole responsibility of the health care provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.

# Permanent J-code checklist

- If you administered LEQVIO<sup>®</sup> before July 1, 2022, and submit for reimbursement after July 1st, you must still use the miscellaneous J-code J3490 or C-code C9399
- Make sure everyone in the practice is aware of the permanent J-code J1306 for LEQVIO. The permanent J-code J1306 must be used when LEQVIO is administered on or after July 1, 2022, including those facilities previously using the miscellaneous C-code C9399
- Update your billing software to reflect the permanent J-code J1306, new units: 284 units per syringe, and expected reimbursement
- During the benefits verification process, confirm the permanent J-code J1306 has been added to the health plan's system to help with the adjudication process
- When using the permanent J-code J1306, Box 19 on the CMS-1500 and Box 80 on the CMS-1450 are no longer required to be populated
- Understand your payer contracts and how they may be adjusted by the permanent J-code J1306
- Review claims to verify that they are processed correctly according to the permanent J-code J1306
- Re-validate prior authorizations with the permanent J-code J1306, if the prior authorizations were previously validated with the miscellaneous J-code J3490 or C-code C9399

If you have questions about the permanent J-code J1306 for LEQVIO, reach out to your Novartis Access and Reimbursement Specialist.

**References:** 1. Centers for Medicare & Medicaid Services. CMS HCPCS Application Summaries and Coding Recommendations: First Quarter, 2022 HCPCS Coding Cycle. Accessed May 2, 2022. <https://www.cms.gov/files/document/2022-hcpcs-application-summary-quarter-1-2022-drugs-and-biologicals.pdf> 2. Nusgart M. HCPCS coding: An integral part of your reimbursement strategy. *Adv Wound Care*. 2013;2(10):576-582. 3. LEQVIO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2021.

## INDICATION

LEQVIO<sup>®</sup> (inclisiran) injection is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of low-density lipoprotein cholesterol (LDL-C). **Limitations of Use:** The effect of LEQVIO on cardiovascular morbidity and mortality has not been determined.

## IMPORTANT SAFETY INFORMATION

Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, urinary tract infection, diarrhea, bronchitis, pain in extremity and dyspnea.

Adverse reactions led to discontinuation in 2.5% and 1.9% of LEQVIO- and placebo-treated patients, respectively. Discontinuation due to injection site reactions, which included injection site pain, erythema and rash, were 0.2% and 0% of LEQVIO- and placebo-treated patients, respectively.

Please click [here](#) for LEQVIO full Prescribing Information.

LEQVIO and the LEQVIO logo are registered trademarks of Novartis AG.  
Licensed from Alnylam Pharmaceuticals, Inc.